For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

Investigators compared cancer-specific survival rates after synchronous vs metachronous metastasis in patients with surgically treated renal cell carcinoma (RCC).

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic ...

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib ...

For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, ...

Updated findings from the phase 3 ROSELLA trial (NCT05257408) showed that combining relacorilant (Lifyorli) with ...

Young cancer patients with private insurance survive longer due to better access to care and treatment. Coverage instability ...

Metastatic kidney survival rates don’t predict individual outcomes. A number of factors, including overall health, tumor characteristics, and response to treatment, influence prognosis and survival.

Women with stage IV breast cancer detected through screening have a 60% chance of survival ten years after diagnosis. This is in comparison to a survival rate of under 20% of those with stage IV ...